Satralizumab Reduces Risk of Severe NMOSD Relapse Satralizumab Reduces Risk of Severe NMOSD Relapse
Compared with placebo, satralizumab reduces the risk of severe relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news